中国的变应原免疫疗法。
Allergen immunotherapy in China.
作者信息
Yang Yaqi, Li Wenjing, Zhu Rongfei
机构信息
Department of Allergy, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China.
Institute of Allergy and Clinical Immunology, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China.
出版信息
Front Allergy. 2024 Jan 8;4:1324844. doi: 10.3389/falgy.2023.1324844. eCollection 2023.
Allergen immunotherapy (AIT) is an etiological treatment strategy that involves administering escalating doses of clinically relevant allergens to desensitize the immune system. It has shown encouraging results in reducing allergy symptoms and enhancing patients' quality of life. In this review, we offer a thorough overview of AIT in China, examining its efficacy, safety, current practices, and prospects. We further underscore the progress made in AIT research and clinical applications, as well as the distinct challenges and opportunities that China faces in this area.
变应原免疫疗法（AIT）是一种病因治疗策略，包括给予逐步增加剂量的临床相关变应原以使免疫系统脱敏。在减轻过敏症状和提高患者生活质量方面，它已显示出令人鼓舞的效果。在本综述中，我们全面概述了中国的AIT，研究了其疗效、安全性、当前实践和前景。我们进一步强调了AIT研究和临床应用取得的进展，以及中国在该领域面临的独特挑战和机遇。
Zotero 插件